Tatton Consulting supported Sheffield-based University of Sheffield neurodegeneration spinout Crucible Therapeutics in its successful application to Biomedical Catalyst 2024 Round 1: Industry-led R&D, which was awarded £1,795,303 by Innovate UK for the project Targeting RNA nuclear export: A disease-modifying treatment for ALS/FTD. The project’s total Innovate UK grant across all partners was £1,795,303.
About the funded R&D project
ALS, the most common form of motor neurone disease, affects roughly 25,000 patients across the UK and US and causes progressive muscle paralysis, typically leading to death within two to five years of diagnosis. Existing treatments slow progression by months at most. Crucible’s approach targets a nuclear export factor implicated in the nerve cell damage seen in ALS: reducing levels of that factor is intended to cut production of the toxic proteins driving the disease. The project is delivered with the Sheffield Institute for Translational Neuroscience.
Award details
- Total project grant: £1,795,303
- Of which to Crucible Therapeutics: £1,109,150
- Competition: Biomedical Catalyst 2024 Round 1: Industry-led R&D
- Competition year: 2024/25
- Project: Targeting RNA nuclear export: A disease-modifying treatment for ALS/FTD
- Sector: Neurodegenerative disease / gene therapy
- UKRI project record: Gateway to Research, project 10141394
- Dataset: Innovate UK funded projects, published 10 August 2026
Tatton Consulting supported the competitive grant application. The award value, competition and project title above are taken from UKRI’s published record for this project.
See all Innovate UK awards Tatton Consulting has supported on our grant successes page.
